PARP inhibitors as anticancer agents
dc.contributor.advisor | Virág, László | |
dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Orvosi Vegytani Intézet | hu_HU |
dc.contributor.author | Oladapo, Emmanuel Taiwo | |
dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
dc.contributor.opponent | Polgár, Zsuzsanna | |
dc.contributor.opponent | Uray, Iván | |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Orvosi Vegytani Intézet | hu_HU |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Onkológiai Intézet::Onkológiai Tanszék | hu_HU |
dc.date.accessioned | 2021-08-18T11:33:09Z | |
dc.date.available | 2021-08-18T11:33:09Z | |
dc.date.created | 2021-07-26 | |
dc.description.abstract | The PARP enzyme family is a heterogeneous group of enzymes that are involved in a myriad of intracellular processes from maintaining genomic integrity, modulating inflammatory responses, and regulating cellular metabolism, to name a few. PARP 1 and 2 especially are crucial in the detection and repair of DNA lesions. This function of PARPs has made them interesting targets for pharmaceutical modulation for the purpose of treating malignant tumours. Since malignant tumours have a relatively higher rate of DNA mutations coupled with frequently dysfunctional DNA repair systems. | hu_HU |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | angol | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 32 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/321301 | |
dc.language.iso | en | hu_HU |
dc.subject | PARP inhibitors | hu_HU |
dc.subject | Cancer therapy | hu_HU |
dc.subject | PARP enzymes | hu_HU |
dc.subject | DNA repair | hu_HU |
dc.subject.dspace | DEENK Témalista::Orvostudomány::Orvosi vegytan | hu_HU |
dc.subject.dspace | DEENK Témalista::Orvostudomány::Onkológia | hu_HU |
dc.title | PARP inhibitors as anticancer agents | hu_HU |